SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-046439
Filing Date
2024-05-24
Accepted
2024-05-24 08:55:19
Documents
13
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0206741-8ka1_allarity.htm   iXBRL 8-K/A 26826
  Complete submission text file 0001213900-24-046439.txt   204773

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE allr-20240514.xsd EX-101.SCH 3015
3 XBRL LABEL FILE allr-20240514_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE allr-20240514_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0206741-8ka1_allarity_htm.xml XML 4295
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41160 | Film No.: 24981117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)